Symprove for treatment of acute diverticulitis
Research type
Research Study
Full title
Double blind randomised controlled trial of Symprove vs Placebo for treatment of acute diverticulitis.
IRAS ID
186075
Contact name
Savvas Papagrigoriadis
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
1 years, 6 months, 4 days
Research summary
Acute Diverticulitis is a common clinical problem and one of the commonest surgical emergencies. The majority of episodes are treated as outpatients with antibiotics, however it is reported that acute diverticulitis and its complications are responsible for 50,000 emergency hospital admissions per year in the UK with a mortality of around 5%. Around 20% percent of these patients will be readmitted within two years with a second similar attack and there are many patients with multiple hospital admissions over the years.\n\nPatients who are hospitalized with acute diverticulitis, will be approached to participate in the study. Patients who admitted to the Acute Surgical Unit will be identified by the ASU staff and parallel to the conservative surgical management (inpatients who are not going to have surgical intervention) will be recruited to the 12-weeks clinical study. The study is a 12-week course of a probiotic. \nIf the patient who is recruited and participating in the study faces severe pain symptoms of exacerbation of the disease during the follow up period, the researcher will refer this patient to the colorectal consultant surgeon for further management.
REC name
London - Harrow Research Ethics Committee
REC reference
16/LO/0037
Date of REC Opinion
26 Apr 2016
REC opinion
Further Information Favourable Opinion